ABOS (38) IVVD (30) STRO (36) TARA (43) ⌘ Pro Terminal →

Innate Pharma S.A. ADS (IPHA) — RQD Stock Rating Cockpit

$1.46 -2.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.45

Innate Pharma S.A. ADS (IPHA) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $167.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IPHA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IPHA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Innate Pharma S.A. ADS (NASDAQ: IPHA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.46 (-2.67% 1D, market cap $167.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IPHA ranks #271 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IPHA compare to ABOS and IVVD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPHA carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M) and IVVD (Invivyd Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.4M). Among the 5-stock peer group, IPHA leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IPHA?

▼

For Innate Pharma S.A. ADS (IPHA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #271 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.45 (-0.67%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IPHA)Realized 20D OHLCV Swing Band: ±12.1%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY IPHA SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$1.62-11.7% Next Q

Q2 (-2Q)

Grade C$1.43+4.9% Next Q

Q3 (-1Q)

Grade C$1.50-2.7% Next Q

Current

Grade D+$1.46-1.1% Hist 90D α

Trajectory: C (60) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IPHA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IPHA currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.77) and Max Pain ($1.53) forces dealer call-delta covering toward $2.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IPHA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IPHA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

40.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE19% OF RANGE

L: $1$1.46H: $3

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on IPHA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

17/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like IPHA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IPHA)

✓Walkthrough of IPHA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IPHA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.39%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.45H $1.48L $1.44C $1.46VOL 14.8K

RES: $2.79SUP: $1.39SMA50: $1.77SMA200: $1.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IPHA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IPHA Butterfly Map → + Track IPHA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IPHA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IPHA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IPHA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IPHA)

Health Care Rank #271 of 1016 ⚔️ ABOS vs IPHA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IPHA vs. ABOS, IVVD, STRO, TARA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Innate Pharma S.A. ADS (IPHA) ranks #271 by composite RQD confidence (52/100, grade D+) and #598 by equity capitalization ($167.6M). Within this direct 5-issuer industry benchmark cohort, IPHA leads on earnings valuation at N/A trailing P/E, while TARA leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. IPHA currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IPHA ACTIVE Innate Pharma S.A. ADS	D+	52/100	—	—	—	-2.67%	$167.6M	Benchmark Subject
ABOS Acumen Pharmaceuticals Inc.	D-	38/100	—	—	-35.0%	-90.82%	$165.6M	/abos-vs-ipha →
IVVD Invivyd Inc.	E	30/100	—	—	-35.0%	-3.37%	$177.4M	/ivvd-vs-ipha →
STRO Sutro Biopharma Inc.	D-	36/100	—	—	-35.0%	-0.44%	$151.6M	/stro-vs-ipha →
TARA Protara Therapeutics Inc.	D-	43/100	—	—	-34.7%	-1.59%	$148.9M	/tara-vs-ipha →

2. IPHA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Innate Pharma S.A. ADS (IPHA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $167.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IPHA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IPHA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IPHA compare to ABOS and IVVD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IPHA?

Where is IPHA trading relative to its 50-day, 200-day, and 52-week technical levels?

IPHA last traded at $1.46 (-2.67% on volume of 14,784 shares), positioning the stock -17.51% below its 50-day simple moving average ($1.77) and -14.62% below its 200-day simple moving average ($1.71). Across its 52-week range of $1.17 to $2.71, IPHA sits at the 18.8% percentile with a 14-day RSI of 40.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($1.28 to $1.64).

IPHA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IPHA stock right now?

Innate Pharma S.A. ADS (IPHA) currently earns a Roarable Rating of D+ (Sell — SELL) with 52/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is IPHA's 12-month price target and RQD AI Jury consensus?

IPHA's 12-month base price target is $1.42 (range $1.11 to $2.85), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IPHA RQD Cockpit IPHA 12M Forecast IPHA Earnings & Move IPHA Dividends & DRIP IPHA Insiders & 13F IPHA Whale Options IPHA Profit Sankey IPHA News & Why

ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IPHA — Innate Pharma S.A. ADS: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:17:42Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IPHA scores 52 out of 100, a letter grade of D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows. Fundamental Cash Engine: 12 of 20, with ROIC at 0% and FCF yield at 0%. Whale 13F Flow: 8 of 20, reflecting institutional accumulation and options positioning. Insider Conviction: 9 of 20, reflecting SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit: 10 of 20, with beta at 1.0 and sector sensitivity. Forensic Balance Sheet: 13 of 20, with Altman Z at 2.5, Piotroski F at 6 of 9, and Debt/Equity at 0.5.

For a prospective investor, the weakest pillars are the cash engine and insider/institutional flow, each of which signals limited current evidence of earnings-driven demand. The balance sheet pillar is the strongest relative to the others, which means the case rests more on balance-sheet durability than on current profitability. Because the cash-return metrics are reported at 0%, any upside thesis depends on future improvement not visible in this data. The beta of 1.0 indicates market-level sensitivity, so the rating's macro-fit score reflects no sector-specific tailwind visible in the source data. This is an analytical summary, not personalized financial advice.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, two items are listed for IPHA. The first, a market-wire item dated one hour before the data timestamp, flags a price edge-lower to $1.51 with the ADS holding near the middle of its range, marked YELLOW as a market-wire signal. The second, a catalyst item dated three hours before the data timestamp, reports on the Q2 2026 earnings with a wider-than-expected loss that overshadowed a modest stock gain, along with an upward estimate revision, marked GREEN. The earnings item is the more consequential signal, though the source does not provide the loss figures or the revision magnitude. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

Open Questions

What were the actual Q2 2026 loss and revenue figures, and how large was the estimate revision referenced in the earnings catalyst?
What are the cash, debt, and free cash flow amounts underlying the Piotroski and Altman scores?
What are the company's revenue sources and key commercial or clinical programs?
Who are the institutional and insider holders, and what is the direction of recent 13F and Form 4 activity?
Is there any analyst coverage or consensus rating available for IPHA?

IPHA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Innate Pharma S.A. ADS (IPHA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IPHA Debate Forum (3) ↓

🟡 MARKET WIRE https://www.siam.in/ • 9h ago

Innate Pharma (IPHA) Edges Lower to $1.51 as ADS Holds Near the Middle of Its Range - TPO Profile

https://www.siam.in/ report covering Innate Pharma S.A. ADS (IPHA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 12h ago

IPHA Q2 2026 Earnings: Wider-Than-Expected Loss Overshadows Modest Stock Gain - Upward Estimate Revision

https://www.dars.gov.et/ report covering Innate Pharma S.A. ADS (IPHA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

MARSEILLE, France, October 27, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Ph

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 6d ago

5 British Blue Chips For Your Portfolio

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 12d ago

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

MARSEILLE, France, October 21, 2026--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 13d ago

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

MARSEILLE, France, October 20, 2026--Innate Pharma announces conference call for third quarter 2026 business and financial update

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IPHA Bull vs. Bear Conversation Board — What's Your Call at $1.46?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IPHA 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.58 (+8.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IPHA (D+ • RQD 52/100) a Buy at $1.46?

Welcome to the IPHA (Innate Pharma S.A. ADS) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.12 (-23.3%)

Spot @ $1.46

Pump the brakes on IPHA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IPHA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Innate Pharma S.A. ADS expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.69 (+15.8%)

Spot @ $1.46

IPHA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IPHA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.46 (52-wk range $1.17 - $2.71), any beat on forward guidance forces shorts and underweight funds to chase.